Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27689891 | 0.84 | NTRK1 (0.46) | NTRK1JAK2JAK3SRCCCNA2 | |
| SCHEMBL56643 | 0.75 | JAK2 (0.48) | NTRK1JAK2JAK3SRCCCNA2 | |
| SCHEMBL4090176 | 0.73 | NTRK1 (0.48) | NTRK1JAK2IGF1R | |
| SCHEMBL56709 | 0.71 | JAK2 (0.61) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL56710 | 0.71 | JAK2 (0.61) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL27658316 | 0.70 | MKNK1 (0.35) | NTRK1CDK2GSK3BIGF1R | |
| SCHEMBL56941 | 0.69 | NTRK1 (0.60) | NTRK1CCNA2CDK2IGF1R | |
| SCHEMBL4095809 | 0.68 | NTRK1 (0.45) | NTRK1CCNA2CDK2IGF1R | |
| SCHEMBL56660 | 0.67 | NTRK1 (0.64) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL56659 | 0.67 | NTRK1 (0.64) | NTRK1JAK2JAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2009-09-10 | — | — | US | disclosed |
| CN-101119988-A | Chemical compound | ASTRAZENECA AB (SE) | 2008-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | TP53, PDK2, PDK1 | NTRK1 4504/4885JAK2 1236/4885JAK3 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.